FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1845-1846 June 24, 1993 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Those who suffer from psoriasis often elicit one of two responses when others around them learn of their plight. The first is therapeutic advice based on anecdotes and household nostrums; the other is apt to be withdrawal, the avoidance of eye or physical contact. Both responses are inappropriate, but they both emphasize the need for effective, rational, and nontoxic treatment for psoriasis.

Approximately 3 million people in the United States are afflicted by psoriasis. The disease consumes some $2 billion of the money allocated to health care each year¹. Psoriasis does not entail substantial mortality, but it has diminished . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Spuls, P. I., Witkamp, L., Bossuyt, P. M. M., Bos, J. D. (2004). The Course of Chronic Plaque-Type Psoriasis in Placebo Groups of Randomized Controlled Studies. Arch Dermatol 140: 338-344 [Abstract] [Full Text]